SURUNKALI GLOMERULONEFRITDA TUBULOINTERSTITSIAL FIBROZNI ERTA TASHXISLASHDA NOINVAZIV BIOMARKERLARNING (KIM-1, NGAL, TIMP-1) O‘RNI
Vol. 4 No. 6 Part 2 (2026): Центральноазиатский журнал академических исследований 13-17
Abstract
Surunkali glomerulonefrit (SGN) oqibatida terminal buyrak yetishmovchiligi rivojlanishining asosiy determinanti tubulointerstitsial fibroz (TIF) hisoblanadi. Buyrak biopsiyasi TIFni aniqlashda "oltin standart" bo‘lsa-da, uning invazivligi va takroriy qo‘llash imkoniyati cheklanganligi sababli, amaliyotda buyrak gistoarxitektonikasidagi sklerotik o‘zgarishlarni aks ettiruvchi noinvaziv va sezgir biomarkerlarni izlash dolzarb masala bo‘lib qolmoqda.
Keywords:
References
Gilbert, R. E. (2023). Tubulointerstitial Fibrosis in Chronic Kidney Disease: Signaling Pathways and Cell-Type Specification. International Journal of Molecular Sciences, 24(11), 9432.
Humphreys, B. D. (2024). Mechanisms of Renal Fibrosis. Annual Review of Physiology, 86, 423-445.
Ichimura, T., Brooks, C. R., & Bonventre, J. V. (2020). Kim-1/Tim-1: a kidney injury molecule with diverse functions in immunity and tissue repair. American Journal of Physiology-Renal Physiology, 318(5), F1085-F1098.
Sato, Y., & Yanagita, M. (2021). Histopathology of tubular injury and interstitial fibrosis in chronic glomerulonephritis. Clinical and Experimental Nephrology, 25(8), 795-804.
Parikh, C. R., & Bonventre, J. V. (2022). Biomarkers of kidney injury and repair: from bedside to bench and back. Kidney International, 101(4), 682-695.
Devarajan, P. (2021). Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker of kidney disease: an update. Pediatric Nephrology, 36(11), 3455-3467.
Nangaku, M. (2022). Chronic hypoxia as a common mechanism of chronic kidney disease progression. Journal of the American Society of Nephrology, 33(3), 485-492.
Viau, A., El Karoui, K., & Terzi, F. (2023). Lipocalin 2 and NGAL in chronic kidney disease: a double-edged sword. Frontiers in Physiology, 14, 1120491.
Coca, S. G., & Parikh, C. R. (2022). Urinary biomarkers for the evaluation of chronic kidney disease progression. Current Opinion in Nephrology and Hypertension, 31(6), 523-531.
Zakiyanov, O., Kalousová, M., & Tesař, V. (2021). Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases in Chronic Kidney Disease. Biomolecules, 11(12), 1853.
Meng, X. M., Nikolic-Paterson, D. J., & Lan, H. Y. (2022). TGF-beta: the principal driver of kidney fibrosis. Nature Reviews Nephrology, 18(6), 345-364.
Eddy, A. A. (2024). Cellular and molecular mechanisms of renal tubulointerstitsial fibrosis. Kidney International Supplements, 14(1), 12-25.
Zeisberg, M., & Kalluri, R. (2023). Cellular mechanisms of tissue fibrosis. 1. Renal fibrosis. American Journal of Physiology-Cell Physiology, 324(2), C213-C224.
Nkuipou-Kenfack, E., & Mischak, H. (2024). Multimarker panels vs. single biomarkers in chronic kidney disease prognosis. Proteomics – Clinical Applications, 18(2), e2300045.
Perco, P., & Mayer, G. (2025). Non-invasive evaluation of renal fibrosis: Current status and future perspectives. Nephrology Dialysis Transplantation, 40(1), 102-114.
Downloads
Published
Issue
Section
How to Cite
